In the OptiTROP-Breast01 phase 3 trial, patients with metastatic triple-negative breast cancer who received the TROP2-targeted antibody–drug conjugate sacituzumab tirumotecan experienced longer progression-free survival than patients treated with chemotherapy.
- Yongmei Yin
- Ying Fan
- Binghe Xu